GlassScriptPhysician profile
Maria Levin
NPI 1679946198
$2,706.76
in general payments reported to CMS, 2019-2025
14 companies · $1,925 in 2025
The $1,925 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $56.48 · 2022: $211 · 2023: $142 · 2024: $372 · 2025: $1,925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,439.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $914.18 | 2022-2025 | Opzelura, Opzelura |
| Regeneron Healthcare Solutions, INC. | $396.90 | 2024-2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $339.46 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $305.64 | 2025 | Anzupgo, Adbry |
| Organon LLC | $208.63 | 2025 | Vtama |
| Abbvie INC. | $186.30 | 2025 | |
| Lnhc, INC | $88.63 | 2025 | Zelsuvmi |
| Genzyme Corporation | $72.63 | 2024-2025 | |
| Pfizer INC. | $41.48 | 2021-2022 | |
| Ucb, INC. | $36.02 | 2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $34.87 | 2023-2025 | Winlevi |
| Amgen INC. | $30.05 | 2025 | Otezla |
| Becton, Dickinson and Company | $30.00 | 2021 | |
| Verrica Pharmaceuticals INC. | $21.97 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Levin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.